Director
Pharmacokinetic Sciences / Novartis
Basel, Switzerland
Gerard Bruin – Director at Translational medicine/Pharmacokinetic Sciences at Novartis
Gerard Bruin is a clinical pharmacologist at Novartis, Basel, Switzerland He has over 30 years of experience in the pharmaceutical industry, spanning across different functions. He holds a PhD in Analytical Chemistry from the University of Amsterdam. He started his career as a bioanalytical chemist at Ciba in 1992, where he worked on the development of new separation methods such as capillary zone electrophoresis and MALDI MS.
In 2004, he joined a project team to develop the anti-IL-17-A monoclonal antibody Cosentyx which has been approved and on the market since 2014 in various indications. The Novartis Cosentyx®/ secukinumab project team, in which he has been a member until now, has been awarded the 2016 Prix Galien USA Award for Best Biotechnology Product. He is a member of an advisory board at Novartis to guide biologics project teams to develop optimal bridging strategies, for instance on the path from PFS to auto-injector or from IV to SC administration or vice versa.
He authored and co-authored more than 50 peer-reviewed scientific papers and book chapters in the field of analytical chemistry and clinical pharmacology (including the topic of bridging).
https://www.linkedin.com/in/gerard-bruin-8612207.
Disclosure information not submitted.
Workshop: Debunking the Myths of Subcutaneous Drug Delivery
Monday, July 8, 2024
1:00 PM – 5:00 PM CET
